combined effect of photobiomodulation using low energy laser therapy and micro-osteoperforation on the rate of orthodontic tooth movement: a split mouth randomized clinical trial - NIL

Start Date05 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Cerivastatin Sodium

100 Translational Medicine associated with Cerivastatin Sodium

100 Patents (Medical) associated with Cerivastatin Sodium

681

Literatures (Medical) associated with Cerivastatin Sodium

01 Mar 2025·REPRODUCTIVE TOXICOLOGY

Embryotoxicity of statins and other prescribed drugs with reported off-target effects on cholesterol biosynthesis

Article

Author: White, Kaylei ; Ramirez, Daniel ; Hartley, Taryn ; Abdulsalam, Zeenat ; Mansion, Aliyah ; Abdelmagid, Hagir ; Tadjuidje, Emmanuel ; Howe, Emily

Cholesterol plays pivotal cellular functions ranging from maintaining membrane fluidity to regulating cell-cell signaling. High cholesterol causes cardiovascular diseases, low cholesterol is linked to neuropsychiatric disorders, and inborn errors of cholesterol synthesis cause multisystem malformation syndromes. Statins lower cholesterol levels by inhibiting the first, rate-limiting reaction of the cholesterol biosynthesis pathway catalyzed by hydroxymethyl-glutaryl-Coenzyme A reductase (HMGCR). However, they have also been shown to interfere with cellular pathways that are unrelated to cholesterol synthesis. One of the last enzymes of cholesterol biosynthesis, 7-dehydrocholesterol reductase (DHCR7), is often mutated in the Smith-Lemli-Opitz syndrome (SLOS), a multisystem malformation syndrome. Strikingly, recent studies have shown that some prescribed psychotropic pharmaceuticals inhibit its activity. In this study, we used Xenopus laevis as a model organism to test the effects of 8 FDA-approved statins and selected prescribed psychotropic drugs on the developing vertebrate embryo. Drugs were tested at concentrations ranging from 0.1 µM to 50 µM. Embryos were exposed to the drugs from the blastula stage through the swimming tadpole stage with daily medium change. Our data show that statins are heterogenous with respect to their ability to cause embryonic lethality, with simvastatin, pitavastatin, lovastatin, cerivastatin, and fluvastatin being the most toxic ones. Observed phenotypes included delayed development, shortened body axis and pericardiac edema. On the other hand, psychotropic drugs were less embryonic lethal than statins but caused similar phenotypes as well as microcephaly and holoprosencephaly. Our findings suggest that the proximal and distal inhibition of cholesterol biosynthesis have different but overlapping effects on embryonic development.

01 Mar 2024·ACS catalysis

Bacterial Lactonases ZenA with Noncanonical Structural Features Hydrolyze the Mycotoxin Zearalenone

Article

Author: Schatzmayr, Gerd ; Höbartner-Gussl, Andreas ; Fruhauf, Sebastian ; Pühringer, Dominic ; Thamhesl, Michaela ; Djinovic-Carugo, Kristina ; Fajtl, Patricia ; Kunz-Vekiru, Elisavet ; Adam, Gerhard ; Prokop, Zbynek ; Moll, Wulf-Dieter ; Damborsky, Jiri

Zearalenone (ZEN) is a mycoestrogenic polyketide produced by Fusarium graminearum and other phytopathogenic members of the genus Fusarium. Contamination of cereals with ZEN is frequent, and hydrolytic detoxification with fungal lactonases has been explored. Here, we report the isolation of a bacterial strain, Rhodococcus erythropolis PFA D8-1, with ZEN hydrolyzing activity, cloning of the gene encoding α/β hydrolase ZenA encoded on the linear megaplasmid pSFRL1, and biochemical characterization of nine homologues. Furthermore, we report site-directed mutagenesis as well as structural analysis of the dimeric ZenA_Re of R. erythropolis and the more thermostable, tetrameric ZenA_Scfl of Streptomyces coelicoflavus with and without bound ligands. The X-ray crystal structures not only revealed canonical features of α/β hydrolases with a cap domain including a Ser-His-Asp catalytic triad but also unusual features including an uncommon oxyanion hole motif and a peripheral, short antiparallel β-sheet involved in tetramer interactions. Presteady-state kinetic analyses for ZenA_Re and ZenA_Scfl identified balanced rate-limiting steps of the reaction cycle, which can change depending on temperature. Some new bacterial ZEN lactonases have lower K_M and higher k_cat than the known fungal ZEN lactonases and may lend themselves to enzyme technology development for the degradation of ZEN in feed or food.

01 Feb 2024·Current medicinal chemistry

Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis

Article

Author: Lou, Dandi ; Zheng, Dingcheng ; Zhang, Xingfen ; Ma, Xueqiang ; Wu, Feng ; Fu, Rongrong

Background::

Previous studies have found a potential role for statins in liver cancer prevention.

Objective::

This study aimed to explore the effect of different types of statins on the incidence of liver cancer.

Methods::

Relevant articles were systematically retrieved from PubMed, EBSCO, Web of Science, and Cochrane Library databases from inception until July 2022 to explore the relationship between lipophilic statins or hydrophilic statins exposure and the incidence of liver cancer. The main outcome was the incidence of liver cancer.

Results::

Eleven articles were included in this meta-analysis. The pooled results showed a reduced incidence of liver cancer in patients exposed to lipophilic statins (OR=0.54, p < 0.001) and hydrophilic statins (OR=0.56, p < 0.001) compared with the non-exposed cohort. Subgroup analysis showed that both exposures to lipophilic (Eastern countries: OR=0.51, p < 0.001; Western countries: OR=0.59, p < 0.001) and hydrophilic (Eastern countries: OR=0.51, p < 0.001; Western countries: OR=0.66, p=0.019) statins reduced the incidence of liver cancer in Eastern and Western countries, and the reduction was most significant in Eastern countries. Moreover, atorvastatin (OR=0.55, p < 0.001), simvastatin (OR=0.59, p < 0.001), lovastatin (OR=0.51, p < 0.001), pitavastatin (OR=0.36, p=0.008) and rosuvastatin (OR=0.60, p=0.027) could effectively reduce the incidence of liver cancer, unlike fluvastatin, cerivastatin and pravastatin.

Conclusion::

Both lipophilic and hydrophilic statins contribute to the prevention of liver cancer. Moreover, the efficacy was influenced by the region and the specific type of statins used.

News (Medical) associated with Cerivastatin Sodium

19 Dec 2024

·www.globenewswire.com

Certa Therapeutics Expands GPR68 Platform through Acquisition of OccuRx

Strengthened Pipeline Targets Multiple Fibrotic DiseasesMELBOURNE, Australia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today announces the acquisition of OccuRx, a Melbourne-based biotechnology company with highly complementary assets, resources and expertise, and a shared focus on targeting GPR68, a master switch of fibrosis. The acquisition combines the assets and capabilities of two companies founded by a leader in the GPR68 field, Professor Darren Kelly, consolidating a pipeline that now includes two Phase 2 and one Phase 1 clinical candidates. Building on Professor Kelly’s pioneering research into inhibitors of GPR68 and benefiting from years of further development within biotechnology and major pharma companies, Certa’s pipeline aims to tackle fibrotic diseases upstream of other targeted biological pathways. Certa’s lead programme is asengeprast (FT011) a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs, which has shown favourable efficacy, safety and pharmacokinetics in patients with systemic sclerosis (scleroderma or SSc). Post the acquisition, Certa’s pipeline will include the additional asset OCX063 from OccuRx which has successfully completed a Phase 1 clinical trial and is in development for focal segmental glomerulosclerosis (FSGS), a rare disease characterized by fibrosis developing in the kidney glomerulus. In addition, Certa also has CTA382, a second-generation compound with the same chemical backbone as Asengeprast, that is under development to treat chronic kidney disease and a third-generation series of pre-clinical GPR68 antagonists, based on a different chemical backbone. Assets from this series are being developed for other fibrotic conditions and wider therapeutic indications. Professor Darren Kelly, Certa Therapeutics’ CEO and founder, said, “Fibrotic diseases are an area of significant unmet need, responsible for an estimated 45% of all deaths globally and representing a $15 billion market. We believe GPR68 is a critical ‘master switch’ of fibrosis and through this acquisition we have brought together a unique pipeline and a passionate, experienced team which is uniquely equipped to drive its development. We look forward to rapidly advancing our programs and, ultimately, developing new safe, effective precision therapies for patients.” Asengeprast has its genesis in Fibrotech, which was sold to Shire in 2014. When Shire was then acquired by Takeda in 2018, Brandon Capital Partners and Uniseed had an opportunity to reinvest in the asengeprast clinical program by forming Certa Therapeutics, and to develop GPR68-targeting ophthalmology assets by forming OccuRx. The two companies have raised $30m (AU$44.5m) over the past six years to advance these assets. Certa will now seek to raise a series B to continue the clinical development of its pipeline and expand its operations. Dr Chris Nave, chair of Certa Therapeutics and Managing Partner of lead investor Brandon Capital, said, "Bringing together the assets and expertise of Certa Therapeutics and OccuRx under one company creates a powerful platform to advance transformative therapies for fibrotic diseases. This consolidation reinforces Certa’s leadership in the GPR68 field and its commitment to developing innovative treatments with a promising clinical-stage pipeline of GPR68 antagonists.” For further information please contact Media – AustraliaKirrily Davis, E: kdavis@bcpvc.com M: +61 (0)401 220228 Media - InternationalSue Charles, Charles Consultants E: sue.charles@charles-consultants.com M: +44 (0)7968 726585 About Certa TherapeuticsCerta Therapeutics is a clinical-stage biotechnology company pioneering innovative precision therapies for the treatment of fibrotic diseases—an area of significant unmet need, responsible for an estimated 45% of all deaths globally and representing a $15 billion market. Certa’s platform targets a critical 'master switch' of fibrosis, GPR68 (a defined G protein-coupled receptor (GPCR)), with a pipeline of inhibitors for various fibrotic indications. Asengeprast (FT011), the company’s lead program, is being developed as a novel, first-in-class oral therapy for systemic sclerosis (scleroderma, SSc) and has successfully completed a multi-national, phase II clinical trial. Scleroderma is a potentially-life threatening autoimmune disorder with the highest mortality rate among rheumatic diseases. The FDA has granted asengeprast (FT011) Orphan Drug Designation and Fast Track status for SSc. Certa's pipeline includes further programs targeting major indications such as chronic kidney disease, focal segmental glomerulosclerosis, diabetic nephropathy, and other chronic fibrotic conditions. Based in Melbourne, Australia, Certa is supported by venture investors Brandon Capital and Uniseed. More information at https://certatherapeutics.com/ Follow us on LinkedIn: https://www.linkedin.com/company/certa-therapeutics/

Phase 1Fast TrackAcquisitionOrphan DrugPhase 2

06 Sep 2022

·endpts.com

Bayer agrees to pay $40M to settle kickback, safety claims sparked by whistleblower

More than a decade after its first day in court, Bayer is finally settling two Department of Justice whistleblower cases. The federal agency announced Friday that Bayer agreed to pay a $40 million fine to resolve “alleged violations of the False Claims Act in connection with the drugs Trasylol, Avelox and Baycol.” The settlement was sparked by two whistleblower lawsuits, both filed by ex-Bayer marketing employee Laurie Simpson in a saga going back close to 15 years. The former employee filed a case in 2008 against Bayer, which was later transferred to the district court in Minnesota. In that case, the employee alleged that the pharma’s statin drug, Baycol, caused risks of rhabdomyolysis, a life-threatening complication of certain drugs that occurs when muscles break down into the blood.

16 Oct 2019

·www.biospace.com

6 Major Drug Recalls from the Past

Patients take a doctor's prescription, believing that their doctor knows best, and the vast majority of the time that is correct. So it can be quite a shock when a recall happens on well-known prescription drugs because of possible health issues. Zantac, a popular H2 receptor blcoker that treats extreme cases of heartburn or recurring acid reflux, was recently added to the list of products getting pulled off the shelf. Unfortunately, Zantac and similar drugs that block the production of acid in the stomach are showing a connection to the development of stomach cancer. GlaxoSmithKline has officially recalled Zantac as a "precaution." It’s always big news when popular drugs get pulled off the shelf. Here are six major recalls from the past worth noting: Valsartan, Losartan and Irbesartan It's technically three drugs, but all three are within the same family and serve the same function. Additionally, all three drugs were part of recalls for the same issue. These common blood pressure medications have had over 75 recalls in recent years because of impurities that could be cancer-causing. Valsartan, Irbesartan and Losartan aren't directly linked to cancer. However, during the refining process, each has produced batches with impurities that have led to cancer and numerous recall incidents. Accutane Accutane was widely prescribed to treat acne for roughly three decades. Then after thousands of lawsuits and millions paid out in verdicts, it was recalled. The recall cited several severe side effects. With the use of Accutane, patients were at risk of experiencing inflammatory bowel disease as well as suicidal tendencies. Anyone using Accutane when pregnant was in danger of miscarriage, premature birth and children at greater risk for congenital disabilities. As a result, production of this popular drug ended entirely by Roche. Generic variations still produced today but the use of them has significantly diminished. Vioxx Over a four and a half year span, Vioxx resulted in nearly 28,000 cardiac deaths or heart attacks. Vioxx was used by over 20 million people and even had Olympic athletes featured in ads for the pain medication. The average rate of heart attacks works out to about 4 per every 1,000 people who used the drug. The manufacturer, Merck, pulled the drug after identifying the substantially increased possibility of a stroke or heart attack. Raptiva Efalizumab or Raptiva was a psoriasis treatment that was eventually found to onset a brain infection called leukoencephalopathy. This brain infection is extremely rare but lethal. Essentially, leukoencephalopathy causes the white matter of the brain to become inflamed, resulting in damaged white matter and ultimately damage to the central nervous system. In early 2009 the FDA announced a Public Health Advisory, which notified the healthcare community of these risks associated with Raptiva. The manufacturer then voluntarily removed the product from the market. Darvocet and Darvon The Darvocet recall received quite a bit of publicity when the common pain treatment was found to lead to many serious heart rhythm risks. Heart rhythm abnormalities, which were not only severe but frequently fatal, caused Xanodyne Pharmaceuticals to pull the brand name opioid medication. The FDA requested the generic producers of the drug, Darvon, to follow Xanodyne's example and remove their products as well. At one point in time, Darvocet was among the most popular pain treatments in both Europe and the United States. Now it is completely banned throughout the U.S. and the U.K. Lipobay The direct competitor to Lipitor, Lipobay, treated high-cholesterol, and was meant to prevent heart disease. Bayer manufactured this drug through the late 1990s but ultimately pulled it in 2001. Lipobay presented the risk of rhabdomyolysis, which causes muscle breakdown. Then the deteriorated muscle tissue clogs the kidneys leading to renal failure. After 52 deaths connected with Lipobay, the drug was removed from the global market. Why Do Medication Recalls Happen? In some cases, such as Lipobay, the medications become available through surrogate endpoints. With surrogate endpoints, the new drug uses the clinical data of similar drugs to receive approval without clinical trials. Recalls for these drugs usually happen because of unexpected differences that change the outcome of use for patients. In other cases, new medication does go through extensive testing, research, development, and refinement. Recalls are still possible even after successful clinical trials. Zantac's recall, for instance, is happening because of an impurity in manufacturing, whereas the drug itself is not the problem.

100 Deals associated with Cerivastatin Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D00889	Cerivastatin Sodium	C10AA06	DB00439

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dyslipidemias	US	Bayer Pharmaceuticals Corp.	26 Jun 1997
Hypercholesterolemia	US	Bayer Pharmaceuticals Corp.	26 Jun 1997

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASGCT2024	Not Applicable	-	-	Novel Micro-Dystrophin Constructs (GL1 Micro-Dystrophin)	thzlqtqwzo(wibcloghap) = njwyubnafn ywituxjfvf (imllmwhqyf )	-	07 May 2024
				Novel Micro-Dystrophin Constructs (GL2 Micro-Dystrophin)	thzlqtqwzo(wibcloghap) = lgnryrvvrf ywituxjfvf (imllmwhqyf )
APAO2024	Not Applicable	Corneal epithelial degeneration	-	Micro Pulse Cyclophotocoagulation (MP-CPC) (Patients with intractable corneal epithelial disorder)	kfubogzacn(infwppncjn) = gvsxbacsls rxwzgchifz (plqqwsgyuk )	-	22 Feb 2024
SNMMI2023	Not Applicable	-	-	Novel kinetic micro-parameter estimation (Proposed PCDE)	esmxwkfvkr(dgexkffsut) = oqcshcrivg orpfsruxyg (hijtmqvszf ) View more	-	28 Aug 2023
				Novel kinetic micro-parameter estimation (LSE-based framework)	esmxwkfvkr(dgexkffsut) = gjhplognal orpfsruxyg (hijtmqvszf ) View more
AAO2022	Not Applicable	Glaucoma	125	Trabecular Micro-Bypass	kyifrseyyd(zligqorvhe) = aobkmhuraj lybukpeulz (liykfxkpzm )	Positive	29 Sep 2022
				Trabecular Micro-Bypass	kyifrseyyd(zligqorvhe) = hlxikedhrz lybukpeulz (liykfxkpzm )
iStent inject RCT (AAO2020)	Not Applicable	Glaucoma, Open-Angle	-	iStent Inject Trabecular Micro-Bypass	qnldycluuo(xmsvprvcwz) = djrtcsplsc odygmupgef (ooquczecvn, 2.75)	Positive	13 Nov 2020
				iStent Inject Trabecular Micro-Bypass	qnldycluuo(xmsvprvcwz) = fdoaqsahha odygmupgef (ooquczecvn, 2.58)
ARVO2020	Not Applicable	Ocular Hypertension \| Glaucoma	70	Trabecular Micro-Bypass (iStent)	tepawqnrhn(jncgnvsdyq) = 73 eyes didn't have any intraoperative complication and 5 had significant hyphema obscuring the view (resulting in abandoning insertion in 1 case). In 1 eye an iris cleft was caused. In 2 eyes the insertion was abandoned without hyphema. In 1 case the second implant did not release. ghrtyojmqh (ynthpajwsa ) View more	-	01 Jun 2020
				Trabecular Micro-Bypass (iStent inject)
2019 ARVO Annual Meeting (ARVO2019)	Not Applicable	Cataract \| Glaucoma	213	Trabecular Micro-Bypass Stent (iStent group)	hizwmfeget(humoxlptny) = qwzzhooxaz gkhveqjnew (fiomvmsmmw ) View more	Positive	01 Jul 2019
				Trabecular Micro-Bypass Stent (Control group)	hizwmfeget(humoxlptny) = rdubjkvhrr gkhveqjnew (fiomvmsmmw ) View more
PO117 (AAO2018)	Not Applicable	Glaucoma	105	CyPass Micro-Stent	xuyhuuraps(svdfcsbrml) = woywcfghmh izhmgirnpo (zwlxetrnrw, 6.3)	Positive	28 Oct 2018
AAIC2017	Not Applicable	miR-144-5p \| miR-374 \| miR-221	-	MICRO-RNA 221 (miR-221)	alqrgmjsta(doibynuufx) = ogenlxbtai oseczckdsv (jgclbaqqgp )	-	01 Jul 2017
ASGCT2010	Not Applicable	Adenoviridae Infections	-	Micro-Dystrophin (Pre-existing AAV8 antibodies)	puixrbtkxl(qfnfixqwif) = yqdvvqkili qjnhwrmoua (uiwssbpbqv )	-	01 May 2010
				Micro-Dystrophin (No pre-existing AAV8 antibodies)	puixrbtkxl(qfnfixqwif) = xsdemayoic qjnhwrmoua (uiwssbpbqv )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis